Clinical observation on the treatment of childhood refractory idiopathic thrombocytopenic purpura with Dihuang Zhixue Capsule ()

详细信息    查看全文

• 作者：Qing-chi Liu (1)
  Wei-hai Wu (1)
  Da-yong Wu (1)
  Xin-wang Feng (1)
  Ya-hui Ma (1)
  Jian-ying Li (1)
  Yu-hui Pang (1)
  Shu-hua Song (1)
  
• 关键词：refractory idiopathic thrombocytopenic purpura ; Dihuang Zhixue Capsule ; cooling blood and dispelling toxic substances
• 刊名：Chinese Journal of Integrative Medicine
• 出版年：2008
• 出版时间：June 2008
• 年：2008
• 卷：14
• 期：2
• 页码：132-136
• 全文大小：80KB
• 参考文献：1. Kappers-Klunne MC, van’t Veer MB. Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy. Br J Haematol 2001;114:121-25. CrossRef
  2. Emilia G, Morselli M, Luppi M, et al. Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura. Blood 2002;99:1482-485. CrossRef
  3. Perrotta S, Amendola G, Locatelli F, et al. Treatment with short-term, high-dose cyclosporin A in children with refractory chronic idiopathic thrombocytopenic purpura. Br J Haematol 2003;121:143-47. CrossRef
  4. Duan T, Chang Y, Liu JL. Short-term observation of cyclosporin A in the treatment of refractory chronic idiopathic thrombocytopenic purpura. Chin J Intern Med (Chin) 2000;39(9):630.
  5. Wang CQ, Li D. Observation of cyclosporin A in the treatment of refractory chronic idiopathic thrombocytopenic purpura. Modern Med J (Chin) 2002;30(2):94-5.
  6. Yang N, Cai J. Clinical observation of cyclosporin A in the treatment of refractory chronic idiopathic thrombocytopenic purpura. J Pract Diagn Ther (Chin) 2002;16(4):286-87.
  7. Zhang ZN, ed. Standard for diagnosis and therapeutic efficacy of hematopathy. 2nd ed. Beijing: Science Press, 1998: 279-82.
  8. Cines DB, Blanchette VS. Immue thrombocytopenic purpura. N Engl J Med 2002; 346: 995-008. CrossRef
  9. Kahan BD. Cyclosporine. N Engl Med 1989;321:1725-738.
  10. Ma J, Fan QL. The influence of dried / Radix Rehmanniae on I a antigen expression of peritoneal macrophage in the mice model of yin defi cincy induced by corticosterone. Pharmacol Clin Chin Materia Med (Chin) 1998;14 (2):22-4.
  11. Wang B, Ge ZD, Zhou AW, et al. Effects of total glucosides of mudan cortex on functions of three types of immune cells / in vitro. Chin Pharmacol Bull (Chin) 1999;15(1):63-5.
  12. Zhou XL, Li YW, Li FC, et al. The experimental study of panax natoginseng saponins on immune functions of rats. J Guangxi Med Univ (Chin) 2001;18(3):360-61.
  13. Yang SL, Liu F. Suppressive effects of rubidate on immune function. Chin Pharmacol Bull (Chin) 1996;12(5):447.
  14. Han JY, Tan DH, Wang MW. Study on hemostatic effect of hydrolysate of Bubalus Bubalis. Pract Pharm Clin Rem (Chin) 2004;7(3):17-8.
  
• 作者单位：Qing-chi Liu (1)
  Wei-hai Wu (1)
  Da-yong Wu (1)
  Xin-wang Feng (1)
  Ya-hui Ma (1)
  Jian-ying Li (1)
  Yu-hui Pang (1)
  Shu-hua Song (1)
  
  1. Department of Hematology, Ping’an Hospital, Shijiazhuang Municipal Doctorial Institute of Hematology, Shijiazhuang, 050021, China
  

文摘

Objective To observe the clinical effect of Dihuang Zhixue Capsule (, DZC, a Chinese preparation for cooling blood and dispelling toxic substances) in the treatment of childhood refractory idiopathic thrombocytopenic purpura (RITP), with cyclosporin A (CsA) used as the control. Methods Forty-one children of RITP were randomized into the treated group and the control group. The 21 patients in the treated group were orally given 2 to 3 DZC capsules each time, thrice a day and the 20 in the control group were given 3 mg/kg CsA per day, with 3 months as one therapeutic course. The therapeutic efficacy, platelet count and adverse reaction in the two groups were compared at the end of the course. Results (1) In the treated group, 1 (4.8%) patient was evaluated as cured, 3 (14.3%) as markedly effective, 5 (23.8%) as effective, 5 (23.8%) as improved, 7 (33.3%) as ineffective, with the total effective rate being 66.7%; while in the control group, the corresponding numbers were 0, 2 (10.0%), 2 (10.0%), 3 (15.0%), 13 (65.0%) and 35.0%, respectively, showing statistical significance in difference between the total effective rates of the two groups (ξ2=4.11, P=0.0426). (2) As compared with the baseline, the platelet count increased in both groups after 2 months-treatment (P<0.05). After 3 months-treatment, the platelet count was higher in the treated group than in the control group (P<0.05). (3) The improvement of hemorrhage in the treated group after 8 weeks-treatment was better than that in the control group (P<0.05). (4) No apparent adverse reaction was observed in the treated group, while in the control group, hirsutism was shown in 15 cases; gingival hyperplasia in 10; digestive reaction in 5, liver function impairment in 5, hypertension in 2 and renal impairment in 2. Conclusion The therapeutic efficacy of DZC is better than that of CsA, and DZC shows good compliance but brings no obvious adverse reaction.